News | February 10, 2011

Hospital Study Demonstrates CT System’s Cost Savings With Stroke


February 10, 2011 – A study at Millard Fillmore Circle Gates Hospital in Buffalo, N.Y., found that Toshiba imaging equipment presented significant benefits, both for the patients and hospital.

To quantify the results of utilizing the Aquilion ONE for acute stroke, the hospital conducted a non-controlled study to measure the impact of 320-detector row dynamic volume CT. It evaluated data from before and after the system’s installation and addressed the top three discharging ICD-9-CM codes.

Prior to installing the system, most patients were imaged using pre-MRI screening and X-ray imaging, limited brain MRI, MR perfusion and MRA of the head and neck. Utilizing the Aquilion ONE showed a significant shift in the diagnostic workup for acute stroke. The expanded use of CT during stroke diagnosis resulted in reduced healthcare costs and improved patient outcomes, as MR is more user-intensive and costly. Furthermore, the images produced by CT allowed patients to be moved more quickly into intervention.

“With stroke accounting for 1 in every 18 deaths in the U.S. and costing the healthcare system approximately $50 billion a year, advanced imaging technologies are allowing us to diagnose stroke more accurately and efficiently than ever before,” said Elad Levy, M.D., FACS, FAHA, professor of Neurosurgery, University at Buffalo Neurosurgery, and director of endovascular stroke service for the Gates Stroke Center. “The whole brain perfusion and digital angiography capabilities of the Aquilion ONE provide our clinicians with the information needed to evaluate the penumbra or the region impacted by the stroke, quickly and accurately.”

On average, patients who were scanned on the system had their hospital stay reduced by nearly half a day. Additionally, for just the three ICD-9-CM codes studied, Millard Fillmore achieved an estimated annualized savings of more than $750,000 by utilizing the system to diagnose acute stroke.

For more information: www.medical.toshiba.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now